Dr. Reddy’s launches Clofarabine Injection in US market

14 Nov 2017 Evaluate

Dr. Reddy’s Laboratories has launched Clofarabine Injection, a therapeutic equivalent generic version of Clolar (clofarabine) Injection in the United States market, approved by the US Food & Drug Administration (USFDA). Clolar is a registered trademark of Genzyme Corporation.

Dr. Reddy’s Laboratories’ Clofarabine Injection is available in single-dose, 20 mL flint vials containing 20 mg of clofarabine in 20 mL of solution (1mg/mL). The Clolar brand and generic had US sales of around $53 million MAT for the most recent twelve months ended in September 2017, according to IMS Health.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.


Dr. Reddys Lab Share Price

1267.15 -7.90 (-0.62%)
08-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×